Genfit S.A. (NASDAQ:GNFT) Short Interest Update

Genfit S.A. (NASDAQ:GNFT) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totalling 51,300 shares, a decrease of 23.0% from the April 30th total of 66,600 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily volume of 13,200 shares, the days-to-cover ratio is currently 3.9 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Genfit in a report on Friday, February 7th.

Institutional Trading of Genfit

An institutional investor recently bought a new position in Genfit stock. OLD Mission Capital LLC purchased a new position in shares of Genfit S.A. (NASDAQ:GNFT) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 22,238 shares of the company’s stock, valued at approximately $76,000. Institutional investors own 2.24% of the company’s stock.

Genfit Trading Up 4.7%

Shares of NASDAQ:GNFT opened at $4.48 on Wednesday. Genfit has a 12 month low of $2.55 and a 12 month high of $6.42. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61. The company has a 50-day moving average price of $3.86 and a 200 day moving average price of $3.81.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.